Elan Corp. (ELN) said it will pay shareholders dividends from its royalties from multiple- sclerosis drug Tysabri in a challenge to a $6.5 billion bid from RP Management LLC for the Dublin-based drugmaker.
Biogen Idec Inc. on Feb. 6 agreed to buy Elan’s stake in the Tysabri drug for $3.25 billion in cash plus future royalties. The drug generated $1.6 billion in sales in 2012. Elan said today it will pay shareholders dividends directly linked to Tysabri’s market performance as a 20 percent share of the royalty received from Biogen Idec.
RP Management offered to buy Elan on Feb. 25, saying a sale would allow shareholders to avoid the substantial risks of Chief Executive Officer Kelly Martin’s plan to make purchases with the proceeds from Tysabri.
Martin said today that together with a $1 billion share- repurchase program announced Feb. 22 and plans to buy additional drug assets, the dividend provides shareholders “significant near- and longer-term benefits.”
To contact the reporter on this story: Kim McLaughlin in Stockholm at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com